Advertisement
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
No AccessJournal of UrologyAdult Urology1 Oct 2014

Nationwide Population Based Study of Infections after Transrectal Ultrasound Guided Prostate Biopsy

    View All Author Information

    Purpose:

    Transrectal ultrasound guided biopsy is the gold standard for detecting prostate cancer but international reports suggest that increasing risks are associated with the procedure. We estimated incidence and risk factors for infection after prostate biopsy as well as 90-day mortality using a nationwide Swedish sample.

    Material and Methods:

    We performed a population based study of 51,321 men from PCBaSe between 2006 and 2011. Primary outcome measures were dispensed prescriptions of antibiotics for urinary tract infection and hospitalization with a discharge diagnosis of urinary tract infection. Multivariable logistic regression was used to examine risk factors for infection in men who underwent prostate biopsy.

    Results:

    During the 6 months before biopsy the background incidence of urinary tract infection was approximately 2%. Within 30 days after biopsy 6% of the men had a dispensed prescription for urinary tract antibiotics and 1% were hospitalized with infection. The strongest risk factors for an antibiotic prescription were prior infection (OR 1.59, 95% CI 1.45–1.73), high Charlson comorbidity index (OR 1.25, 95% CI 1.11–1.41) and diabetes (OR 1.32, 95% CI 1.17–1.49). Risk of an antibiotic prescription after biopsy decreased from 2006 to 2011 (OR 0.79, 95% CI 0.70–0.90) but the risk of hospital admission increased (OR 2.14, 95% CI 1.58–2.94). No significant increase was observed in 90-day mortality.

    Conclusions:

    Severe infections with hospitalization after prostate biopsy are increasing in Sweden. The risk of post-biopsy infection is highest in men with a history of urinary tract infection and those with significant comorbidities.

    References

    • 1 : Single-dose antibiotic prophylaxis in core prostate biopsy: Impact of timing and identification of risk factors. Eur Urol2006; 50: 832. Google Scholar
    • 2 : Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology2002; 60: 826. Google Scholar
    • 3 : Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol2012; 61: 1110. Google Scholar
    • 4 : Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol2010; 183: 963. LinkGoogle Scholar
    • 5 : Complications after prostate biopsy: data from SEER-Medicare. J Urol2011; 186: 1830. LinkGoogle Scholar
    • 6 : Infection after transrectal core biopsies of the prostate—risk factors and antibiotic prophylaxis. Br J Urol1996; 77: 851. Google Scholar
    • 7 : Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol2007; 41: 456. Google Scholar
    • 8 : Cohort profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol2013; 42: 956. Google Scholar
    • 9 : Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol2008; 42: 352. Google Scholar
    • 10 : The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf2007; 16: 726. Google Scholar
    • 11 : Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol2011; 29: 1335. Google Scholar
    • 12 : Residual urinary volume and urinary tract infection—when are they linked?. J Urol2008; 180: 182. LinkGoogle Scholar
    • 13 : A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum prior to transrectal ultrasound-guided prostate biopsy. J Urol2012; 189: 1326. Google Scholar
    • 14 Socialstyrelsen: The National Board of Health and Welfare Statistics in the Areas of Health and Medical Care, 2009. Available at http://192.137.163.40/epcfs/FisFrameSet.asp?FHStart=ja&W=1440&H=900. Accessed December 13, 2013. Google Scholar
    • 15 Dohnhammar U, Edlund C and Edquist P: SwedRes 2011. Available at http://www.folkhalsomyndigheten.se/documents/projektwebbar/barn/swedres-2011.pdf. Accessed January 24, 2014. Google Scholar
    • 16 : No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU Int2011; 107: 1912. Google Scholar
    • 17 : Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men. Int J Cancer2008; 123: 647. Google Scholar
    • 18 : External review and validation of the Swedish national inpatient register. BMC Public Health2011; 11: 450. Google Scholar
    • 19 : Current routines for transrectal ultrasound-guided prostate biopsy: a web-based survey by the Swedish Urology Network. Scand J Urol Nephrol2012; 46: 405. Google Scholar
    • 20 : Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol2004; 171: 1478. LinkGoogle Scholar
    Advertisement